Cholera toxin: A paradigm of a multifunctional protein

Indian Journal of Medical Research

Volumn 133, Issue 2, 2011, Pages 179-187

  Bharati, Kaushik ^a   Ganguly, Nirmal K ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Adjuvant; Cholera toxin; Immunomodulation; Immunotherapy

Indexed keywords

BEHCET DISEASE PEPTIDE RECOMBINANT CHOLERA TOXIN B SUBUNIT CONJUGATE; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CHOLERA TOXIN B SUBUNIT INSULIN CONJUGATE; CHOLERA TOXIN B SUBUNIT MYELIN BASIC PROTEIN CONJUGATE; CHOLERA TOXIN WO7; CHOLERA VACCINE; CTA1 DD ISCOM FUSION PROTEIN; ENTEROTOXIN; RECOMBINANT CHOLERA TOXIN B SUBUNIT; UNCLASSIFIED DRUG; ADENOSINE DIPHOSPHATE; IMMUNOLOGIC FACTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BEHCET DISEASE; CHOLERA; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREDICTION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; ANIMAL; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY;

ADENOSINE DIPHOSPHATE; ANIMALS; AUTOIMMUNE DISEASES; CHOLERA TOXIN; CHOLERA VACCINES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY;

EID: 79952982703     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Pacini F. Osservazioni microscopiche e deduzioni patologiche sul colera asiatico. Gazzetta Medica Italiana Federativa 1854.
2. Koch R. An address on cholera and its bacillus. Dtsch Med Wochenschr 1884; 10: 111. (English translation in: Br Med J 1884; ii: 403-7, 453-9).
3. De SN. Enterotoxicity of bacteria-free culture filtrate of Vibrio cholerae. Nature 1959; 183: 1533-4.
4. Dutta NK, Panse MV, Kulkarni DR. Role of cholera a toxin in experimental cholera. J Bacteriol 1959; 78: 594-5.
5. Finkelstein RA, Norris HT, Dutta NK. Pathogenesis experimental cholera in infant rabbits. 1. Observations on the intraintestinal infection and experimental cholera produced with cell-free products. J Infect Dis 1964; 114: 203-16.
6. Finkelstein RA, LoSpalluto JJ. Pathogenesis experimental cholera: preparation and isolation of choleragen and choleragenoid. J Exp Med 1969; 130: 185-202.
7. Finkelstein RA, LoSpalluto JJ. Production of highly purified choleragen and choleragenoid. J Infect Dis 1970; 121 (Suppl): S63-S72.
8. Lonnroth I, Holmgren J. Subunit structure of cholera toxin. J Gen Microbiol 1973; 76: 417-27.
9. King CA, van Heyningen WE. Deactivation of cholera toxin by a sialidase monosialosylganglioside. J Infect Dis 1973; 127: 639-47.
10. Dallas WS, Falkow S. Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin. Nature 1980; 288: 499-501.
11. Zhang RG, Scott DL, Westbrook ML, Nance S, Spangler BD, Shipley GG, et al. The three-dimensional crystal structure of cholera toxin. J Mol Biol 1995; 251: 563-73.
12. Zhang RG, Westbrook ML, Westbrook EM, Scott DL, Otwinowski Z, Maulik PR, et al. The 2.4 A crystal structure of cholera toxin B subunit pentamer: choleragenoid. J Mol Biol 1995; 251: 550-62.
13. Sixma TK, Pronk SE, Kalk KH, Wartna ES, van Zanten BA, Witholt B, et al. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature 1991; 351: 371-7.
14. Sixma TK, Kalk KH, Van Zanten BA, Dauter Z, Kingma J, Witholt B, et al. Refined structure of Escherichia coli heatlabile enterotoxin, a close relative of cholera toxin. J Mol Biol 1993; 230: 890-918.
15. Kaper JB, Morris JG Jr, Levine MM. Cholera. Clin Microbiol Rev 1995; 8: 48-86.
16. Merritt EA, Sarfaty S, van den Akker F, L'Hoir C, Martial JA, Hol WG. Crystal structure of cholera toxin B-pentamer bound to receptor GM1 pentasaccharide. Protein Sci 1994; 3: 166-75.
17. Majoul IV, Bastiaens PI, Soling HD. Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: studies with cholera toxin in Vero cells. J Cell Biol 1996; 133: 777-89.
18. Feng Y, Jadhav AP, Rodighiero C, Fujinaga Y, Kirchhausen T, Lencer WI. Retrograde transport of cholera toxin from the plasma membrane to the endoplasmic reticulum requires the trans-Golgi network but not the Golgi apparatus in Exo2-treated cells. EMBO Rep 2004; 5: 596-601.
19. Fujinaga Y, Wolf AA, Rodighiero C, Wheeler H, Tsai B, Allen L, et al. Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulum. Mol Biol Cell 2003; 14: 4783-93.
20. Hazes B, Read RJ. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 1997; 36: 11051-4.
21. Tsai B, Rapoport TA. Unfolded cholera toxin is transferred to the ER membrane and released from protein disulfide isomerase upon oxidation by Ero1. J Cell Biol 2002; 159: 207-16.
22. Walia K, Ghosh S, Singh H, Nair GB, Ghosh A, Sahni G, et al. Purification and characterization of novel toxin produced by Vibrio cholerae O1. Infect Immun 1999; 67: 5215-22.
23. Bhattacharyya S, Ghosh S, Shant J, Ganguly NK, Majumdar S. Role of the WO7-toxin on Vibrio cholerae-induced diarrhoea. Biochim Biophys Acta 2004; 1670: 69-80.
24. Northrup RS, Fauci AS. Adjuvant effect of cholera enterotoxin on the immune response of the mouse to sheep red blood cells. J Infect Dis 1972; 125: 672-3.
25. Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 1998; 391: 851.
26. Lycke NY. Cholera toxin promotes B cell isotype switching by two different mechanisms. cAMP induction augments germ-line Ig H-chain RNA transcripts whereas membrane ganglioside GM1-receptor binding enhances later events in differentiation. J Immunol 1993; 150: 4810-21.
27. Gagliardi MC, De Magistris MT. Maturation of human dendritic cells induced by the adjuvant cholera toxin: role of cAMP on chemokine receptor expression. Vaccine 2003; 21: 856-61.
28. Eriksson K, Fredriksson M, Nordström I, Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect Immun 2003; 71: 1740-7.
29. Bromander A, Holmgren J, Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol 1991; 146: 2908-14.
30. Gagliardi MC, Sallusto F, Marinaro M, Langenkamp A, Lanzavecchia A, De Magistris MT. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol 2000; 30: 2394-403.
31. Yankelevich B, Soldatenkov VA, Hodgson J, Polotsky AJ, Creswell K, Mazumder A. Differential induction of programmed cell death in CD8+ and CD4+ T cells by the B subunit of cholera toxin. Cell Immunol 1996; 168: 229-34.
32. Elson CO, Holland SP, Dertzbaugh MT, Cuff CF, Anderson AO. Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J Immunol 1995; 154: 1032-40.
33. Elson CO, Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 1984; 132: 2736-41.
34. Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986; 59: 301-8.
35. Ågren LC, Ekman L, Löwenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997; 158: 3936-46.
36. Czerkinsky C, Russell MW, Lycke N, Lindblad M, Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun 1989; 57: 1072-7.
37. Chen KS, Strober W. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: disproportionate cholera toxin enhancement of the IgA B cell response. Eur J Immunol 1990; 20: 433-6.
38. Abraham E, Robinson A. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia. Vaccine 1991; 9: 757-64.
39. Liang XP, Lamm ME, Nedrud JG. Oral adminstration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. J Immunol 1988; 141: 1495-501.
40. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 1993; 61: 4272-9.
41. Rollwagen FM, Pacheco ND, Clemens JD, Pavlovskis O, Rollins DM, Walker RI. Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine 1993; 11: 1316-20.
42. Bourguin I, Chardès T, Bout D. Oral immunization with Toxoplasma gondii antigens in association with cholera toxin induces enhanced protective and cell-mediated immunity in C57BL/6 mice. Infect Immun 1993; 61: 2082-8.
43. Walsh EE. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine 1993; 11: 1135-8.
44. Pappo J, Thomas WD Jr, Kabok Z, Taylor NS, Murphy JC, Fox JG. Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis. Infect Immun 1995; 63: 1246-52.
45. Akhiani AA, Nilsson LA, Ouchterlony O. Effect of cholera toxin on vaccine-induced immunity and infection in murine schistosomiasis mansoni. Infect Immun 1993; 61: 4919-24.
46. Debard N, Buzoni-Gatel D, Bout D. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect Immun 1996; 64: 2158-66.
47. Yamamoto M, McDaniel LS, Kawabata K, Briles DE, Jackson RJ, McGhee JR, et al. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun 1997; 65: 640-4.
48. Bäckström M, Lebens M, Schödel F, Holmgren J. Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. Gene 1994; 149: 211-7.
49. Sanchez J, Svennerholm AM, Holmgren J. Genetic fusion of a non-toxic heat-stable enterotoxin-related decapeptide antigen to cholera toxin B-subunit. FEBS Lett 1988; 241: 110-4.
50. Ryan ET, Butterton JR, Zhang T, Baker MA, Stanley SL Jr, Calderwood SB. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice. Infect Immun 1997; 65: 3118-25.
51. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 1992; 22: 2277-81.
52. Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998; 187: 1123-32.
53. Yamamoto S, Takeda Y, Yamamoto M, Kurazono H, Imaoka K, Yamamoto M, et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 1997; 185: 1203-10.
54. Yamamoto S, Kiyono H, Yamamoto M, Imaoka K, Fujihashi K, Van Ginkel FW, et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 1997; 94: 5267-72.
55. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 1997; 65: 2821-8.
56. Sanchez J, Wallerstrom G, Fredriksson M, Angstrom J, Holmgren J. Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (Sta-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. J Biol Chem 2002; 277: 33369-77.
57. Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, et al. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J Immunol 2001; 167: 3398-405.
58. Adamsson J, Lindblad M, Lundqvist A, Kelly D, Holmgren J, Harandi AM. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin. J Immunol 2006; 176: 4902-13.
59. Cong Y, Oliver AO, Elson CO. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur J Immunol 2001; 31: 64-71.
60. Burkart V, Kim Y-E, Hartmann B, Ghiea I, Syldath U, Kauer M, et al. Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide. J Immunol 2002; 168: 1730-7.
61. Chen P, Li J, Barnes J, Kokkonen GC, Lee JC, Liu Y. Restraint of proinflammatory cytokine biosynthesis by Mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 2002; 169: 6408-16.
62. Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994; 91: 10795-9.
63. Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 1996; 93: 7196-201.
64. Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94: 4610-4.
65. Sobel DO, Yankelevich B, Goyal D, Nelson D, Mazumder A. The B-subunit of cholera toxin induces immunoregulatory cells and prevents diabetes in the NOD mouse. Diabetes 1998; 47: 186-91.
66. Sun J-B, Raghavan S, Sjöling A, Lundin S, Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp 3+CD25+ and Foxp3-CD25-CD4+ regulatory T cells. J Immunol 2006; 177: 7634-44.
67. Phipps PA, Stanford MR, Sun J-B, Xiao B-G, Holmgren J, Shinnick T, et al. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur J Immunol 2003; 33: 224-32.
68. Stanford M, Whittall T, Bergmeier LA, Lindblad M, Lundin S, Shinnick T, et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 2004; 137: 201-8.
69. Stål P, Befrits R, Rönnblom A, Danielsson A, Suhr O, Stahlberg D, et al. Clinical trial: safety and short-term efficacy of recombinant cholera toxin B-subunit (rCTB) in the treatment of active Crohn's disease. Aliment Pharmacol Ther 2010; 31: 387-95.